encourag comment recoveri strong posit
thursday april abbott report first-quart result came januari
expect recent adjust street target attempt account
revenu growth came organ basi adjust earn
growth came nutrit establish pharmaceut came
expect off-set medic devic diagnost start see earli impact
follow quarter manag withdrew full-year guidanc
get better clariti recoveri process
said abbott remain modestli optimist expect suggest
busi expos hospital-bas demand may seen trough could see
recoveri second half year manag cite experi china
asian countri saw earlier impact start rebound grant
much lower util remain level team also
offset declin given diagnost segment span entir gamut test
offer ad potenti much billion revenu remaind
year area focus continu believ abbott
play key role entir test paradigm deal pandem
also believ abbott enviabl posit regard capit alloc
cash posit rel medic technolog compani posit
compani well maintain support dividend payout also give signific
strateg flexibl complet potenti though believ may take time
take-out candid accept recent lower valuationsand thu near-term
opportun may prove around cash-poor companiesov time believ
abbott could becom aggress strategi view histor savvi
manag team board director relat though mani intern
invest pan except well recent alon satisfi
acknowledg abbott complet immun headwind believ
diversifi portfolio strong balanc sheet make one best posit large-cap
medic devic name deliv rel stabl result take advantag market
disloc next quarter move post-covid world expect
abbot benefit robust end-market demand segment margin expans
pipelin new product gain traction back substanti invest strong
cash flow creat accret opportun believ support current multipl
time ep room upsid result number lever compani
abbott highli diversifi provid medic devic nutrit pharmaceut product
return equiti ttm
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
risk thesi includ impact lower-than-expect sale caus competit compani
key market lower reimburs rate product respect procedur slower-than-anticip adopt
util product among physician and/or patient bottom line abbott ep growth depend
oper effici could materi off-set invest within compani grow product line
global compani abbott exposur sever intern countri introduc oper fx risk
diversif help off-set headwind first-quart result demonstr benefit abbott diversifi
portfolio strength establish pharmaceut epd nutrit collect sale grow high
singl digit offset weak medic devic lesser degre diagnost segment expect
nutrit maintain acceler growth rate first-quart growth basi point
due bulk orders/pantri stuf expect rel stabil nutrit epd help off-set headwind
segment like medic devic diagnost estim full year epd nutrit growth
respect overal abbott histor receiv investor pushback keep diversifi portfolio
versu anoth divestitur think prove valuabl set asset allow compani
remain focus invest long-term growth initi continu deliv sharehold valu
prolong recoveri period expect look rest largest relat headwind
expect medic devic segment sale global delay elect urgent procedur
lost case may eventu reschedul elect side abbott note expect
somewhat prolong recoveri period reach pre-covid procedur level like toward end perhap
except medic devic weak abbott freestyl libr post anoth impress quarter growth
continu momentum april reorder patient add howev given uncertainti
surround elect procedur potenti prolong recoveri period manag withdrawn full year
see sign stabil modest improv low earlier-hit geographi abbott seen weekli
improv china case volum total sale sinc start reopen countri februari
volum remain pre-covid peak hand geographi like unit state europ still
rel earli quarantin subsequ reopen process though manag note geographi also
seen stabil suggest may alreadi trough
big question remain around pace recoveri manag suggest would like v-shape
optimist second half push later call point manag admit ultim shape
 still unclear may look like potenti said medic devic provid larg treat
patient whose cardiolog procedur delay somewhat ultim complet abbott prove
see medic devic revenu reacceler faster pace mani large-cap peer result expect second
quarter see largest headwind forecast approxim organ sale declin quarter
growth improv rest year third fourth quarter
critic player diagnost abbott receiv signific public effort across test market
test compani play molecular space point-of-car hospital-bas product
recent made stride enter latest segment test test individu antibodi relat
compani abl nearli off-set test volum reduct diagnost segment
see impact fewer individu interact healthcar system routin test look forward would expect
attent busi remain extraordinarili high administr mani health offici continu tout
abbott product portfolio discuss
id follow emerg use author eua end march product gotten hype
today system placement unit state though system custom one
white hous current run test current manufactur assay per day
impli test per system per day look forward team think increas capac
million test june would welcom develop said realiti type volum
benefit product remain limit especi compar bigger system market
rapid point care instrument like enter market soon includ immunoassay system
outperform outperform expect hear
near futur model approxim million revenu platform
remaind
lab-bas system capabl run test period today system
use throughout unit state current instal base impli total throughput
million test per month assum test run million current produc monthli
basi look forward team note begun place system field around thu far
signific instal base outsid unit state team feel fulfil demand
model approxim million revenu platform remaind
antibodi test wednesday compani announc avail igg antibodi test run
architect design detect antibodi viru develop time current
team commit ship million test end month ramp million
end june team also look add igm antibodi test portfolio though sure whether
combin igg test run stand-alon run separ would limit capac patient
would like requir model approxim million revenu platform
remaind
final compani develop rapid igg/igm antibodi later flow test specif given
extrem cautiou use rapid antibodi test given high fals posit seen test ilk
overal antibodi test repres massiv test opportun given mani hundr million peopl may need
test potenti multipl time howev util test logist get run kept us
overli enthusiast impact abl make detail discuss pleas see note took
antibodi test turn im convinc hype prematur
rest busi core lab point care test come signific pressur due reduct touch
point healthcar system attempt take consider model fortun abbott
offset rest portfolio
link recent deep dive report test unit state
strong cash posit provid flexibl abbott cash balanc continu grow billion plu billion
untap credit facil leav well posit weather near-term impact continu invest long-term
growth initi provid flexibl way deploy assets/return capit sharehold estim abbott net
debt/ebidta roughli time compar time follow close st jude acquisit earli
believ decreas leverag provid abbott flexibl opportunist though expect
manag somewhat patient wait attract valuat synergi standpoint opportun
relat specif capit alloc commentari manag reiter focu increas payment
dividend april invest new product alin roll-out manufactur capac tact share repurchas
though expect smaller prioriti given today valuat continu debt paydown matur
abbott tend light potenti detail continu expect compani look leverag strong
balanc sheet either multipl tuck-in acquisit larger transform deal especi rel lower
valuat medic devic
diabet continu strong momentum despit headwind libr benefit abbott acceler dtc
salesforc expans effort expand reimburs coverag system rel low cost difficult
quantifi manag also note uptick libr order shelter-in-plac order expand unit
state europ patient look secur adequ suppli quarantin period expect build-up
suppli first quarter could provid small headwind growth patient need work
inventori believ abbott still earli phase realiz benefit dtc salesforc initi
allow sustain momentum beyond estim intens manag diabet
market penetr leav ampl room sustain growth estim full year growth
compar approxim declin total medic devic sale
addit libr detail quarter includ total sale million report basi year-over-year
estim global libr user base increas sequenti million global patient made
million patient intern market respect impli patient
add flat sequenti year-over-year manag highlight new prescript
compar fourth quarter lag sale due time shipment
term pipelin manag reiter confid libr on-going discuss fda
icgm approv unit state though time provid note expect expand launch libr
addit countri abbott also recent donat libr sensor hospit help
physician monitor patient glucos level without need close contact could provid earli experi
expand market opportun hospit though limit commerci expect channel
robust data collect sum think first-quart result demonstr libr uniqu posit rapidli grow cgm
market expect abbott remain well posit benefit sustain market growth come year
guidanc due uncertainti surround durat sever relat impact manag
full year lower sale estim billion organ basi
report basi compar prior estim sale billion organ report
lower adjust ep estim previous
full year lower sale estim billion organ basi report basi
compar prior estim sale billion organ report lower
adjust ep estim previous
